We will have limited operations from 15:00 Wednesday 24 December 2025 (AEDT) until Friday 2 January 2026. Find out how to contact us during the holiday period.
APO-ONDANSETRON ODT, IPCA-ONDANSETRON ODT, TN-ONDANSETRON ODT, PTIN-ONDANSETRON ODT, PIP-ONDANSETRON ODT , GTA-ONDANSETRON ODT (Apotex Pty Ltd)
Product name
APO-ONDANSETRON ODT, IPCA-ONDANSETRON ODT, TN-ONDANSETRON ODT, PTIN-ONDANSETRON ODT, PIP-ONDANSETRON ODT , GTA-ONDANSETRON ODT
Sponsor
Date registered
Evaluation commenced
Decision date
Approval time
205 working days (255)
Active ingredients
Ondansetron
Registration type
New generic medicine
Indication
APO-ONDANSETRON ODT, IPCA-ONDANSETRON ODT, TN-ONDANSETRON ODT, PTIN-ONDANSETRON ODT, PIP-ONDANSETRON ODT, GTA-ONDANSETRON ODT (tablets) is indicated for the prevention and treatment of nausea and vomiting induced by cytotoxic therapy and radiotherapy.